Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

PHESGO®▼ (pertuzumab/trastuzumab)
Prescribing Information

For details of the enhanced Pregnancy Prevention Programme, please click on the prescribing information links below.
Herceptin® (trastuzumab) IV 150 mg UK
Perjeta® (pertuzumab) UK
Herceptin® (trastuzumab) SC 600 mg UK
PHESGO®▼ (pertuzumab/trastuzumab) UK

Breast Resource Hub

 

An educational resource hub for Roche Breast Cancer Medicines for UK Healthcare Professionals.

Always refer to the relevant Summary of Product Characteristics (UK) before treating a patient.

Explore resources
Phesgo Home Page
PHESGO Expert Exchange
 HER2+ Breast Cancer 
Product
Watch how to prepare PHESGO for SC administration
Promotional video series created in collaboration with UK Breast Oncologists.

Prefer to talk things through? We’re here to speak with you about supporting your HER2+ eBC patients

Connect with our team
nikhita.govind@roche.com
vic.wallace@roche.com
jo.mccarthy@roche.com
john.danks@roche.com
suki.mahal@roche.com
gaby.roe@roche.com
dare.rotimi@roche.com
alan.young.ay2@roche.com
douglas.gibson@roche.com
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.